Evolus (NASDAQ:EOLS) Posts Earnings Results, Misses Expectations By $0.10 EPS

Evolus (NASDAQ:EOLS - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.10), FiscalAI reports. Evolus had a negative return on equity of 759.04% and a negative net margin of 22.31%.The business had revenue of $68.97 million during the quarter, compared to analysts' expectations of $67.75 million. Evolus updated its FY 2025 guidance to EPS.

Evolus Stock Performance

EOLS traded up $0.40 during trading on Wednesday, reaching $6.81. The stock had a trading volume of 2,329,458 shares, compared to its average volume of 1,141,131. The stock has a market cap of $440.47 million, a PE ratio of -6.95 and a beta of 0.97. Evolus has a one year low of $5.71 and a one year high of $17.44. The business has a 50-day moving average of $6.69 and a 200-day moving average of $8.41.

Wall Street Analyst Weigh In

EOLS has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Evolus in a research report on Tuesday, October 14th. HC Wainwright lowered their price objective on Evolus from $27.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Needham & Company LLC reissued a "hold" rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday, August 6th. Wall Street Zen cut Evolus from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Finally, BTIG Research reissued a "buy" rating and issued a $18.00 target price on shares of Evolus in a research note on Monday, September 8th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $21.25.

Get Our Latest Stock Report on Evolus

Insider Transactions at Evolus

In related news, Director Brady Stewart acquired 30,000 shares of Evolus stock in a transaction dated Friday, August 15th. The shares were purchased at an average cost of $6.82 per share, with a total value of $204,600.00. Following the completion of the purchase, the director owned 88,629 shares of the company's stock, valued at $604,449.78. This represents a 51.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $7.51, for a total value of $42,972.22. Following the transaction, the chief marketing officer directly owned 89,949 shares in the company, valued at $675,516.99. This trade represents a 5.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 5.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of EOLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Evolus by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company's stock valued at $400,000 after buying an additional 1,838 shares during the last quarter. Millennium Management LLC grew its stake in shares of Evolus by 1.7% during the first quarter. Millennium Management LLC now owns 1,392,028 shares of the company's stock valued at $16,746,000 after buying an additional 23,605 shares during the last quarter. Jones Financial Companies Lllp bought a new position in shares of Evolus during the first quarter valued at about $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Evolus by 36.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company's stock valued at $1,883,000 after buying an additional 41,513 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Evolus by 484.8% during the first quarter. Jane Street Group LLC now owns 69,947 shares of the company's stock valued at $841,000 after buying an additional 57,987 shares during the last quarter. 90.69% of the stock is owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Stories

• Five stocks we like better than Evolus
• Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio
• 3 Cash-Rich Stocks With High Growth Potential Right Now
• What is the Shanghai Stock Exchange Composite Index?
• Why Vertical Aerospace Stock Could Double After This Flight Test
• Using the MarketBeat Dividend Yield Calculator
• Amazon: Breakout Confirmed—Here’s Where It Could Go Next

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Evolus Right Now?

Before you consider Evolus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.

While Evolus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here